Specific Biologics Inc., a Toronto-based biotechnology company developing precision gene-editing therapies for serious genetic diseases, has closed an oversubscribed US$35 million Series A financing to advance its lead Dualase® therapeutic candidate for C9ORF72-associated amyotrophic lateral sclerosis (ALS).

The financing was led by Hatteras Venture Partners, with participation from foundational investors Lumira Ventures and adMare BioInnovations, alongside new investors Genesys Capital, Business Development Bank of Canada’s Life Sciences Venture Fund, DeepWorks and Seido Capital.

The proceeds will support the development of Specific Biologics’ lead Dualase® therapeutic candidate through initial clinical biomarker proof-of-concept in the first cohort of an adaptive Phase I/II clinical trial in patients with C9ORF72-associated ALS. Specific Biologics’ proprietary Dualase® platform is designed to precisely remove disease-causing DNA repeat expansions while preserving the normal sequences required for biological function. These abnormal DNA repeat expansions are implicated in more than 40 genetic disorders.

Led by our Toronto office, Norton Rose Fulbright advised Specific Biologics on the Series A financing.